Literature DB >> 16497869

Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.

K J Schmitz1, R Callies, J Wohlschlaeger, R Kimmig, F Otterbach, J Bohr, H-S Lee, A Takeda, K W Schmid, H A Baba.   

Abstract

BACKGROUND AND AIM: The production of prostaglandins is regulated by cyclo-oxygenases (COXs), which also have a role in tumour development and progression in various malignancies, including breast cancer. The mechanisms by which COX-2 contributes to unfavourable prognosis are still poorly understood. The association between expression of COX-2 and possible linked signalling pathways-namely, Akt, extracellular regulated kinases (ERK1/2), the stress-activated kinase p38 or Her-2/neu-is assessed in a series of 113 node-negative breast cancers.
RESULTS: COX-2 was identified as an independent prognostic factor (p = 0.034) in node-negative breast cancer by survival analysis. The lack of a relationship between COX-2 expression and activated Akt, Erk1/2, p38 and Her-2/neu was indicated by statistical analysis.
CONCLUSIONS: The prognostic effect of COX-2 expression on lymph node-negative breast cancer is confirmed-COX-2 is probably not regulated by HER-2, Akt, Erk1/2 or p38. Further studies are necessary for the elucidation of the signalling pathways responsible for the modification of COX-2 expression and the increased aggressiveness of breast cancers overexpressing COX-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497869      PMCID: PMC1860412          DOI: 10.1136/jcp.2005.030650

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  43 in total

Review 1.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; H J Senn
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 2.  Chemoprevention in hereditary colorectal cancer syndromes.

Authors:  E Hawk; R Lubet; P Limburg
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

3.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Authors:  Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

Authors:  C Costa; R Soares; J S Reis-Filho; D Leitão; I Amendoeira; F C Schmitt
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

5.  Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis.

Authors:  Sadik A Khuder; Nabeel A Herial; Anand B Mutgi; Douglas J Federman
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

Review 6.  Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

Authors:  L R Howe; K Subbaramaiah; A M Brown; A J Dannenberg
Journal:  Endocr Relat Cancer       Date:  2001-06       Impact factor: 5.678

7.  Roles of Akt and glycogen synthase kinase 3beta in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes.

Authors:  Q Tang; M Gonzales; H Inoue; G T Bowden
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 8.  Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.

Authors:  Yang Cao; Stephen M Prescott
Journal:  J Cell Physiol       Date:  2002-03       Impact factor: 6.384

9.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

Authors:  Ari Ristimäki; Anna Sivula; Johan Lundin; Mikael Lundin; Tiina Salminen; Caj Haglund; Heikki Joensuu; Jorma Isola
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

10.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.

Authors:  G Pérez-Tenorio; O Stål
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  13 in total

1.  Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.

Authors:  Sertaç Ata Güler; Mustafa Ümit Uğurlu; Handan Kaya; Semiha Şen; Yasemin Nazlı; Bahadır M Güllüoğlu
Journal:  Ulus Cerrahi Derg       Date:  2015-06-01

2.  Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Noureddine Boujelbene; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Tumour Biol       Date:  2010-12-10

3.  Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.

Authors:  Mary Morrogh; Victor P Andrade; Asawari J Patil; Li-Xuan Qin; Qianxing Mo; Rita Sakr; Crispinita D Arroyo; Edi Brogi; Monica Morrow; Tari A King
Journal:  J Surg Res       Date:  2011-06-25       Impact factor: 2.192

4.  COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients.

Authors:  Bar Chikman; Sergey Vasyanovich; Ron Lavy; Liliana Habler; Gleb Tolstov; Andronik Kapiev; Ariel Halevy; Judith Sandbank
Journal:  Med Oncol       Date:  2014-05-10       Impact factor: 3.064

5.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

6.  Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.

Authors:  Kailash Mosalpuria; Carolyn Hall; Savitri Krishnamurthy; Ashutosh Lodhi; D Michael Hallman; Mary S Baraniuk; Anirban Bhattacharyya; Anthony Lucci
Journal:  Mol Clin Oncol       Date:  2014-06-23

7.  Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.

Authors:  Nathalia Serna-Marquez; Socrates Villegas-Comonfort; Octavio Galindo-Hernandez; Napoleon Navarro-Tito; Alejandro Millan; Eduardo Perez Salazar
Journal:  Cell Oncol (Dordr)       Date:  2012-11-21       Impact factor: 6.730

Review 8.  A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.

Authors:  J A Glover; C M Hughes; M M Cantwell; L J Murray
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

9.  Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.

Authors:  B Paquette; H Therriault; G Desmarais; R Wagner; R Royer; R Bujold
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

10.  COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.

Authors:  Swati Kulkarni; Deepa B Patil; Leslie K Diaz; Elizabeth L Wiley; Monica Morrow; Seema A Khan
Journal:  BMC Cancer       Date:  2008-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.